%0 Journal Article
%T 非奈利酮在糖尿病肾病患者中的应用研究进展<br>Research Progress in the Application of Finerenone in Patients with DKD
%A 孟浩洋
%A 王建榜
%J Advances in Clinical Medicine
%P 8325-8329
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.1291199
%X 糖尿病肾病(diabetic kidney disease, DKD)是一种常见的糖尿病并发症，若未在糖尿病肾病早期临床阶段对其进行控制，则该病将进展为终末期肾病(end-stage renal disease, ESRD)。为提高患者的生活质量，降低糖尿病肾病患者的死亡率，药物选择就尤为关键。新型盐皮质激素受体拮抗剂(mineralocorticoid receptor antagonist, MRA)非奈利酮以其高选择性、有效阻断盐皮质激素受体，能有效地保护心、肾，为目前治疗糖尿病肾病的一个新的选择。本文旨在通过分析糖尿病肾病的主要发病机制以及非奈利酮的药理机制、临床应用等方面内容，为后续糖尿病肾病患者应用此药治疗提供一定临床依据。<br />
Chronic kidney disease (DKD) is a common complication of diabetes. If it is not controlled in the early clinical stage, it will develop into end-stage renal disease (ESRD). In order to improve the quality of life of patients and reduce the mortality of patients with diabetes nephropathy, drug se-lection is particularly critical. The new mineralocorticoid receptor antagonist, finerenone, with its high selectivity and effective blocking of mineralocorticoid receptor, can effectively protect the heart and kidney, and is a new choice for the treatment of diabetes nephropathy. The purpose of this article is to provide some clinical basis for the follow-up treatment of diabetes nephropathy by analyzing the main pathogenesis, pharmacological mechanism and clinical application of finere-none.
%K 糖尿病肾病，慢性肾病，非奈利酮，研究进展<br>Diabetic Kidney Disease
%K Chronic Kidney Disease
%K Finerenone
%K Research Progress
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=55702